Low molecular weight heparins (LMWHs) are prepared by enzymatic or chemical depolymerization of standard, unfractionated commercial grade heparin (UFH) resulting in fragments of mean molecular weight ranging from 4000 to 6500,1 Andersson et af.2 showed that the lower the molecular weight of the preparations of heparin, the less effective they were in prolonging the activated partial thromboplastin time (APIT) , due to low molecular weight fragments having a lesser effect on activated thrombin (activated coagulation factor II, IIa). However, the molecular weight does not influence the inhibitory effect on activated factor X (Xa).
© Edward Arnold 1995 from inactivation by ATIII when it is associated with phospholipid within the prothrombinase complex. The differences in the anticoagulant effects of UFH and LMWH have been explained by Jordan et al., 3 Lane et aI. 4 and Ellis et aI. 5 The selective effect on factor Xa ( Figure 1 ) has been shown in preclinical trials to favour the suppression of thrombosis without producing the same anticoagulant and therefore potential haemorrhagic effect of UFH. it is primarily because of this potential for reduced bleeding but maintenance of an equivalent antithrombotic effect that LMWHs have been investigated for use as thromboprophylactic agents and are currently being evaluated in the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE).
LMWHs have other potential advantages over UFH. They do not bind to endothelial cells in culture and have a lower affinity for plasma proteins, platelets and macrophages. There is, therefore, a more predictable response to a fixed dose and a longer half-life which means it may be administered on a once daily basis. LMWHs may also be associated with a lower incidence of heparin-induced thrombocytopenia and allergic reactions. The long-term effects on bone demineralization are still unknown.
LMWHs have been most extensively investigated in trials of thromboprohylaxis in orthopaedic and general surgery. Clinic trials in gynaecological, urological and neurological surgery have also been performed. Recently, 
LMWHs in orthopaedic surgery
Patients undergoing hip and knee joint surgery are at high risk of DVT and PE (Table 1) . Of patients undergoing hip arthroplasty or surgery for hip fracture 23% have DVT located above the knee and they are consequently at the highest risk of fatal and nonfatal PE. Over the last seven years, several meta-analyses have evaluated the efficacy and safety of LMWHs compared with placebo, dextran, UFH and lowdose warfarin in patients undergoing orthopaedic and general surgical procedures. Although metaanalysis is a very useful statistical technique it is not without problems. Its main strength is to combine data from a number of smaller trials, which alone may show a trend in favour of a particular treatment compared with another, yet fail to reach conventional statistical significance. However, great care must be taken when combining potentially heterogeneous data from trials which are likely to have widely differing designs, use different drugs at different doses and have differing diagnostic criteria and methods of screening.
Meta-analysis is also open to publication bias, as negative studies may be under-reported. These problems can be overcome by combining the data from well-designed trials which satisfy predetermined criteria for inclusion. In a review and analysis of orthopaedic trials by Jorgensen et al., 6 LMWHs were found to be superior to placebo in studies of patients undergoing elective hip arthroplasty, knee arthroplasty, tibial osteotomy and repair of femoral neck fracture. Studies reporting the incidence of proximal DVT all showed a reduction in the LMWH treatment group compared with the placebo group. No conclusions could be drawn from the trial data regarding the incidence of PE. A comprehensive, critical analysis of clinical trials of LMWH in orthopaedic surgery was performed by Green et af.7With regards efficacy, they found a 31-79% reduction in the prevalence of DVT in patients given LMWH compared with those given placebo in patients undergoing total hip replacement. In patients undergoing total knee replacement, there was a 71% reduction in the prevalence of DVT compared with placebo.
In trials comparing the efficacy of LMWH with dextran, two different LMWHs were found to be superior to dextran in patients undergoing hip arthroplasty, although the incidence of proximal DVT was not significantly different.s-? No differences were observed in the incidence of PE. However, bleeding events were found to be significantly higher in patients receiving dextran.
The meta-analysis of orthopaedic trials by Nurmohamed et al. lO demonstrated a significant risk reduction of 0.75 (CI 0.56-0.99) for DVT in patients receiving LMWH compared with patients receiving UFH. Although not statistically significant, there was a trend in favour of a reduction in PE. There was no significant difference in major bleeding events. Similar results were found by Leizorovicz et al. ll In their analysis, they found a nonsignificant trend towards a reduction in the incidence of DVT in the patients treated with LMWH compared with UFH (P = 0.07) but no differences were observed in the incidences of PE between the LMWH and UFH groups. A more recent meta-analysis" found that, in studies comparing the efficacy of LMWH with UFH alone or in combination with dihydroergotamine (DHE), overall, LMWHs were at least as effective. They
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also performed a meta-analysis of two studies of patients undergoing hip arthroplasty.P-P In both studies, LMWH was compared with 15 000 units UFH per day. There was a significant reduction in the incidence of DVT in the patients treated with LMWH. Compared with adjusted dose heparin or 15000 units UFH per day, Green et af.7 also found LMWH to be more, or at least as, effective in preventing thromboembolic events.
There has been only one double-blind study comparing LMWH with UFH in patients with hip fracture.> In this study, LMWH was found to be less effective than UFH in preventing DVT. There were 14 (43.7%) positive venograms in the LMWH group (n = 32) compared with six (20%) in the UFH group (n = 30), P < 0.05. There was also a trend towards a reduction in the number of proximal DVTs in favour of the UFH group (five versus 12, p = 0.059).
In a double-blind trial comparing LMWH with warfarin sodium for prophylaxis against DVT after hip or knee arthroplasty, Hull et al. 15 found DVTs in 231 out of 617 patients (37.4%) in the warfarin group and in 185 out of 590 patients (31.4%) in the LMWH group (p = 0.03). With regards to major bleeding events, nine out of 721 patients in the warfarin group (1.2%) and 20 out of 715 patients in the LMWH group (2.8%) had major bleeding events (p = 0.04).
Although only two trials have included screening for PE, meta-analysis of 13 other elective hip trials has shown a higher (though nonsignificant) incidence of PE in the UFH groups. 6 With regards to safety, there were no significant differences in either minor or major bleeding events between the groups of patients treated with LMWH or UFH. One study has shown a reduction in total bleeding events in favour of the LMWH group compared with the UFH group. 12 From the trials and analyses performed so far, LMWHs seem to be at least as efficacious as UFH in preventing postoperative DVT and PE. Several studies and meta-analyses have demonstrated their superiority over UFH, dextran and low-dose warfarin in preventing postoperative DVT. No clear advantage has been demonstrated regarding bleeding complications and, in one study, LMWH produced more postoperative bleeding complications than low-dose warfarin. Further large, double-blind, randomized trials are underway to compare LMWHs with other pharmacological and physical methods of thromboprophylaxis in orthopaedic surgery. Future trials should also address the relative cost of effectiveness of each approach.
LMWHs in general surgery
Patients undergoing general surgical procedures have an overall risk of DVT of approximately 25% and of fatal PE of 0.3-0.8%.16.17 Patients at higher risk are those with intra-abdominal malignancy where the incidence of DVT may be as high as 40% and the incidence of fatal PE 1%. As in orthopaedic surgery, meta-analysis has been used to assess the efficacy and safety of LMWH in general surgical patients. Several meta-analyses 6 , lO,l1 ,18 ,19 have found LMWHs to be at least as efficacious as UFH in preventing postoperative thromboembolism. These studies also showed that LMWHs conferred no benefit with regards to minor or major bleeding events. However, the meta-analysis by Kakkar'? showed that higher doses of LMWH do not result in a lower incidence of DVT, whereas the risk of wound haematoma was dose-dependent. Similar findings were seen in two international, randomized, double-blind, multicentre trials. 17 ,20 The primary end-point in the first trial was safety; 3809 patients undergoing major abdominal surgery received either 2500 IU LMWH once daily or 5000 IU UFH twice daily. Major bleeding events occurred in 69 (3.6%) patients in the LMWH group and 91 (4.8%) patients in the UFH group (p = 0.1). Severe bleeding was less frequent in the LMWH group (1.0% v 1.9%; p = 0.02), as was wound. haem atom a (1.4% v 2.7%;p= 0.007). There was no difference in efficacy between the two groups. Perioperative death rates were 3.3% in the LMWH group and 2.5% in the UFH group which are not significantly different. In the second trial, 1351 patients received either 1750 anti-factor Xa units LMWH once daily or 5000 IU UFH twice a day. The incidence of DVT was 4.8% in the LMWH group and 4.4% in the UFH group. This difference is not significant. However, postoperative bleeding events were less frequent in the LMWHgroup (p < 0.01).
These randomized trials suggest that LMWHs are marginally safer than UFH in patients undergoing major abdominal surgery, although there is no difference in efficacy. Further large-scale studies are underway to assess the efficacy and safety of other LMWH compounds in patients undergoing general surgery, and also to assess the cost effectiveness of LMWHs compared with other forms of thromboprophylaxis. The results of these trials should more clearly define the role of LMWHs in general surgery.
LMWHs in urology
PE is the commonest cause of death following urological surgery.s-However, the incidence of DVT is at least five times higher in those undergoing retropubic prostatectomy compared with transurethral operations. Urological procedures involving laparotomy are frequently included in trials of general surgical patients and, overall, the incidence of DVT is approximately 25%. LMWHs seem to be safe and efficacious in these patients. No large-scale, randomized trials have been performed in patients undergoing transurethral prostatectomy.
DVT occurs frequently in patients undergoing renal transplantation. In a retrospective study of deep venous thrombosis.P 480 consecutive renal transplant operations were reviewed to obtain the incidence of DVT, PE or both. Forty (8.3%) thrombotic events were diagnosed, comprising 25 lower limb DVT alone, 11 DVT with PE and four PE alone. Four deaths were directly attributable to PE, which was the fourth commonest major cause of death in the review period. DVT was more common on the side of the transplant but the difference was not significant. Other studies have shown a higher incidence of fatal PE, occurring in over 4% of patients undergoing renal transplantation.P However, the role of LMWHs in thromboembolic prophylaxis has not been investigated in transplant patients.
LMWHs in gynaecological surgery and pregnancy
The incidence of DVT in patients undergoing gynaecological surgery without thromboprophylaxis is similar to that of patients undergoing general surgical procedures, i.e. approximately 25%; 40% of all deaths following gynaecological surgery are due to PE.24 Furthermore, The National Confidential Enquiry into Perioperative Deaths (NCEPOD) showed that 20% of deaths following hysterectomy were due to venous thromboembolism (VTE). The risk of DVT depends on the type of surgery and, overall, fatal PE occurs in approximately 1% of patients, pelvic and ovarian vein thrombi being particularly common following pelvic surgery. Trials have shown that oral anticoagulants, low-dose heparin, dextran and intermittent pneumatic compression are effective thromboprophylactic agents in patients undergoing gynaecological procedures.25-28 However, few large-scale, randomized trials of LMWH have been performed solely in this group of patients. Borstad et al. 29 compared the thromboprophylactic effect and safety of LMWH given in a dose of 2500 anti-factor Xa units once daily with UFH 5000 units twice daily in 141 patients undergoing gynaecological surgery. In this study, venography was performed when DVT was suspected, the primary end-point being safety. None of the patients developed a clinically detectable DVT but one patient in the LMWH group had a nonfatal PE three days after prophylactic treatment was stopped; 20% of patients in the LMWH group and 14% of patients in the UFH group developed bleeding complications, a difference which is not significant. In a previous study, Borstad et al. 3o compared the efficacy and safety of 5000 antifactor Xa units LMWH administered once daily with 5000 units UFH given twice daily. In this study, although no DVTs were detected using impedance plethysmography, there were significantly more bleeding events and transfusion requirements in patients receiving LMWH. However, the dose of LMWH used in this trial is now accepted to be too high to be used for thrornboprophylaxis and the results are probably not significant. Kaaja et al.» investigated the effects of administration of LMWH 20 mg once daily, UFH 5000 units twice daily and 2500 units UFH given in combination with 0.5 mg DHE twice daily in 100 women undergoing abdominal hysterectomy. There were no thromboembolic complications in any of the three groups. None of the patients in the LMWH group had major bleeding events whereas six patients receiving 5000 units UFH twice daily and two patients receiving UFH in combination with Uses oflow molecular weight heparins 303 DHE required reoperation for major bleeding or blood transfusion (p < 0.05). The results from these trials show no convincing evidence that LMWH is superior to UFH in preventing DVT in patients undergoing gynaecological surgery. However, venography was not mandatory in any of the studies, which implies that the true incidence of DVT was under-reported. Larger randomized studies using sensitive screening tests will be required in order to reliably assess and compare LMWH with other thromboprophylactic agents.
Pregnancy itself is a risk factor of venous thromboembolism and PE is now the leading cause of maternal death in pregnancy and the puerperium. Obesity, age over 35 years, parity of three or greater, previous history of VTE and prolonged bed rest are additional risk factors and thromboprophylaxis should be considered for these women, especially if they are immobilized for any reason, either in the pre-or postpartum period. In most circumstances, thromboprophylaxis should be given to pregnant women undergoing surgery (including caesarean section). Several studies have shown that LMWH appears to be safe for both pregnant mother and fetus.32--35 These studies showed that neither UFH or LMWH cross the placental barrier. In the study by Melissari et al. ,34 seven pregnant women undergoing therapeutic termination of pregnancy were randomized to receive 5000 anti-factor Xa units of LMWH 15 and three hours prior to operation. Eight patients acted as controls. Paired maternal and fetal blood samples were taken before and immediately after the termination for assay of heparin. LMWH was detected in all maternal samples of the test patients but not in any of the fetal samples. A subsequent evaluation of the thromboprophylactic effect of LMWH was performed in 11 pregnant women who were known to have had a severe thromboembolic tendency, recurrent miscarriages and responded poorly to either oral anticoagulants or UFH. All patients receiving LMWH in thromboprophylactic doses completed uneventful pregnancies. There were no haemorrhagic or other complications and bone density scans performed shortly after delivery showed normal mineral mass. Studies to evaluate the safety of treatment of DVT in pregnancy have not yet been performed, but from the above data it would be reasonable to assume that it is at least as safe at UFH.
LMWHs in neurosurgery and stroke
The use of pharmacological agents for thromboprophylaxis in neurosurgical and stroke patients is controversial. Despite a number of trials demonstrating efficacy and safety in these groups of patients,36-40 many clinicians are reluctant to use anticoagulant agents because of the potential morbidity and mortality associated with intracranial and spinal bleeding. However, balanced against this are the risks of DVT and fatal PE. The overall incidence of DVT in neurosurgical patients is approximately 25% and the incidence of PE has been reported to be between 0% and 5%, of which 9-50% are fatal. Spinal cord injury and brain tumours are associated with an incidence of DVT greater than 50% and PE occurs in 3-3.8% of patients with brain tumours. Meningiomas and malignant gliomas are associated with the highest incidence of thromboembolism. The incidence of DVT in stroke patients is 28-75% and the incidence of PE is 2-19.8%. Mortality in those patients with PE ranges from 25-100%. 38 UFH has been evaluated in neurosurgical patients, spinal cord injury and patients with stroke. In a randomized trial of patients undergoing craniotomy there were no reported bleeding complications in the 50 patients receiving lowdose heparin.v' The incidence of DVT in untreated controls was 34% compared with 6% in the low-dose heparin group. No studies have been performed to assess.the efficacy and safety of LMWH in neurosurgical patients. However, Green et a/. 37 evaluated LMWH versus UFH in 41 patients with spinal injury. Using impedance plethysmography and duplex scanning as diagnostic methods, they found the incidence of DVT and fatal PE in the UFH group to be 23.8% and 9.5%, respectively, compared with no DVTs or PE in the LMWH group. In the UFH group the drug was stopped in 10% of the patients because of significant bleeding events whereas there were no significant bleeding events in the LMWH group. In a 60 patient study by Prins et al.,39 although LMWH was more efficacious than control (six DVTs and one PE in the treatment group versus 16 DVTs and six PEs in the control group) there were significantly more haemorrhagic events in the treatment group (five versus two, respectively). There were also nine deaths in the treatment group compared with two in the control group.
Although no firm conclusions can be drawn from these few studies, LMWH may be more efficacious than UFH, but the safety of each has not been proven in neurosurgical and spinal injury patients. Clearly, further large randomized trials are necessary to compare the efficacy and safety of LMWH wth UFH and with intermittent compression devices. A large trial is currently underway to investigate the efficacy and safety of heparin, aspirin or a combination of both in patients with stroke.
LMWHs in medicine and cardiology
Patients with moderate or severe medical illness are at increased risk of mortality developing DVT and subsequent PE. Sandler and Martine! showed that the mortality from PE in medical patients is approximately 1% of all hospital admissions and, overall, fatal PE is three times more common in medical patients than in those undergoing surgical procedures. This figure includes subgroups of high-risk patients such as those with stroke, which have been discussed previously. There have been fewer studies investigating venous thromboembolism in medical patients compared to studies in surgical patients. Clagett et a/. 42 performed an overview of four randomized trials (n = 263) and found the incidence of objectively diagnosed DVT in the control groups to be 24% (CI 18-30%). Using 125I-fibrinogen leg scanning, Belch et a/. 43 found DVT in 26% of patients with heart failure. In a group of medical patients, a .third of whom had either heart failure or malignancy, Harenburg et a/. 44 found evidence of DVT in 3.6% and 4.5% of patients receiving LMWH and UFH, respectively. It is evident from these trials that in moderate-or high-risk medical patients, both UFH and LMWH are efficacious in reducing the incidence of VTE. They also appear to be safe. It remains to be seen whether LMWH will be found to be superior to UFH with regard to efficacy and safety in large-scale, randomized trials.
The role of anticoagulants in patients undergoing percutaneous transluminal coro~ary angioplasty (PTCA) , coronarr a~tery s.tentmg, unstable angina, postmyocardJaI infarction and following thrombolysis is still under investigation. Acute thrombosis following PTCA, arterial stenting and reocclusion following t.hrombolysis remains a significant problem despite the routine use of intravenous heparin and antiplatelet agents. Late occlusion or significant restenosis secondary to smooth muscle cell hyperplasia occurs in up to 40% of patient~~ndergoing PT~A and leads to significant morbidity and m0T!ahty. Several new anticoagulant agents are under mvestigation for the prevention of acute thrombosis, rethrombosis and restenosis. These include recombinant hirudins, monoclonal antibodies to platelet membrane glycoprotein IIblIIIa, potent antiplatelet inhibitors, specif!c .factor Xa. inhibitors and LMWHs. There is limited expenmental evidence that LMWH may reduce the incidence of late occlusion secondary to intimal hype.rplasia. Schmid et al. 45 investigated the effects of mcreasing doses of LMWH on restenosis in 41 patie~ts undergoing PTCA. At three months, following repeat coronary angiography, they found that restenosis occurred in only five out of 37 (14%) evaluable patients. Buchwal~".~/.46 found that administration of LMWH slgmflcantly reduced neointimal hyperplasia following inserti?n of vascular stents into the coronary artenes of hypercholesterolaemic minipigs. Results. are awaited from trials investlgatmg the efficacy and safety of LMWHs in the adjunctive t~eatment of myocardial infarction and unstable angina.
LMWHs in renal dialysis
UFH has traditionally been used to prevent thrombosis on the membrane filter during renal dialysis but recently the efficacy and safety of LMWH has also been established. Schrader et al. 47 compared the efficacy and safety of UFH with LMWH in patients commencing haemodialysis. There were similar incidences of thrombus formation in the extracorporeal circulation (1.59% and 1.33% in the LMWH and UFH groups, respectively) and no significant differences between the two groups with regard to bleeding events. However, more blood
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transfusions were required in the UFH group. A significant increase in plasma triglycerides was observed in the UFH group but not in the LMWH group, a finding which was confirmed in a trial of 22 patients receiving haemodialysis over a 12-month period. 48 Following baseline lipid measurements, patients receiving long-term renal dialysis were switched from UFH to LMWH for six months. During the LMWH treatment, total cholesterol was reduced and there was a significant decrease in LDL (low-density lipoprotein) cholesterol with only a minor fall in HDL (highdensity lipoprotein) cholesterol. These changes were reversed when UFH was recommended in place of LMWlf. Baumelou et al. 49 investigated the pharmacokinetics of LMWH in ten p~tients u.ndergoingh~~modialysis. Dialysis using either high-permeability or low-permeability membranes did not significantly alter the pharmacokinetics of LMWH compared with healthy volunt~ers. During treatment, no clotting was observed m the extracorporeal circuits and there were no bleeding events. In a dose ranging study, Ryan et al. 50 found a bolus dose of 2500 anti-factor Xa units of LMWH to be sufficient for ?ialysis la~ting up to four hours. For dialysis lastmg up to SIX hours, 5000 anti-factor Xa units given as a bolus were as effective as UFH given as a 5000 unit~olus plus an infusion of 1500units per hour.
It IS apparent from these studies that, in chronic haemodialysis patients, LMWHs are safe and efficacious. A potential benefit of the long-term use of LMWH in dialysis patients is a reduction in cardiovascular risk factors. It is also likely that LMWHs, because of their longer half-life and greater bioavailability will be effective when administered as a single bolus dose.
LMWHs in cardiopulmonary bypass
Exp~rience of LMWHs in patients undergoing cardiopulmonary bypass (CPB) is limited. In thẽ rst reported case, LMWH was used successfully m the extracorporeal system of a patient with heparin-induced thrombocytopenia.s-Several studies have been performed in animal models. Bagge et al. 52 compared LMWH with UFH in 33 pigs undergoing cardiopulmonary bypass with respect to clotting, bleeding and the effects of protamine. They found that, despite adequate anti-factor Xa activity, inhibition of thrombin was crucial for the prevention of clotting. Protamine efficiently normalized the activated clotting time in the LMWH group but left a residual 20% anti-factor Xa activity. However, this did not increase the bleeding tendency. In a canine model of cardiopulmonary bypass, Koza et aI.53 compared the anticoagulant effects of LMWH with UFH. Postoperative blood loss and fibrinogen deposition showed no significant difference between the two groups. At the present time there is insufficient evidence from animal work to show that LMWH is superior to UFH. Clearly, clinical trials in humans are required to establish the place of LMWHs in CPB.
LMWHs in arterial surgery
Both UFH and LMWH have been shown to be safe and effective venous thromboprophylactic agents in patients undergoing aortic or peripheral vascular surgery.s-Other antithrombotics are used extensively in vascular surgical practice. Antiplatelet agents are used as prophylaxis against arterial thrombosis, and long-term anti platelet therapy is often given to protect against postoperative arterial thrombosis occurring both at the site of surgery and elsewhere in the vascular tree. Despite these prophylactic measures, acute thrombosis and restenosis remain the commonest cause of both autologous vein and prosthetic graft failure. In addition, restenosis occurs in up to 40% of coronary arteries and 50% of superficial femoral arteries within the first year of angioplasty.V UFH and LMWH have been shown to inhibit smooth muscle cell proliferation and intimal hyperplasia in animal models. 5 6-59 LMWH has theoretical advantages over antiplatelet therapy in maintaining vascular graft patency by virtue of its superior antithrombotic effect and more potent antiproliferative activity on vascular smooth muscle cells. The hypothesis that LMWH would be more efficacious than aspirin + dipyridamole in maintaining graft patency was tested prospectively in a multicentre trial of 200 patients undergoing femoropopliteal bypass grafting.w Patients were randomized to receive either a daily injection of 2500 IU LMWH, or 300 mg aspirin combined with 100 mg dipyridamole eight hourly, for three months.
There were 94 patients randomized to the LMWH group and 106 to the aspirin + dipyridamole group. Patients were stratified according to indication for surgery and were followed-up for one year. Analysis of patency at six months showed 87% graft survival in the LMWH group and 72% in the aspirin + dipyridamole group (54% less graft occlusions in the LMWH group). At 12 months the respective figures were 78% and 64% (39% less graft occlusions in the LMWH group). Separate analysis for the claudication and salvage surgery groups revealed similar results in those undergoing surgery for claudication with 76% graft survival in the LMWH group and 83% in the aspirin + dipyridamole group. However, the respective figures for graft survival in patients undergoing salvage surgery were 82% and 45%, a highly significant result (p = 0.0006). This trial demonstrated that LMWH is superior to aspirin + dipyridamole in maintaining femoropopliteal graft patency in patents with critical limb ischaemia undergoing salvage surgery. Further studies investigating the role of LMWH in arterial surgery are awaited.
LMWHs in the treatment of DVT
Intravenous UFH given for five days, along with oral anticoagulation continued for three to six months has been the mainstay of DVT treatment for many years. However, intravenous heparin therapy has several disadvantages. Patients are required to remain in hospital, are connected to infusion pumps (often for several days) and serial blood samples are required in order to ensure that the activated partial thromboplastin time remains in the therapeutic range. LMWHs, because of their more predictable response at fixed doses, greater bioavailability and longer half-life have the potential advantages of a once daily subcutaneous injection without the need for monitoring. Green et aJ.7 analysed nine randomized, prospective studies comparing LMWH with adjusted-dose UFH for the treatment of DVT. In each of these studies, objective tests were used for diagnosis, assessing haemorrhagic outcomes and detecting recurrent thrombosis. There were 652 patients in the LMWH arm of the study and 656 patients in the UFH arm. A reduction in thrombus size was seen in 64% and 50% and an increase in thrombus size seen in 6% and 12%, respectively, p < 0.001. Follow-up t~omboembolic complications were documented in four of the studies and occurred in 2.7% (12/439) and 7.0% (31/443), respectively, a risk reduction of 61% (P < 0.005). Safety assessment in all nine studies also showed a benefit for LMWH over UFH with major bleeding occurring in six (0.9%) and 21 (3.2%), risk reduction 68%, p < 0.005, as did mortality, which was recorded in four studies, with lower mortality in the LMWH group, 19 (4.3%) versus 36 (8.1%), risk reduction 47%, p < 0.03. It is likely that LMWHs given subcutaneously will replace intravenous UFH as the treatment of choice for DVT and several LMWHs have already been licensed for this purpose.
LMWH and malignancy
Patients undergoing cancer surgery hav~a highrisk of developing both VTE and bleeding, they therefore require speci~1 consideratio~.. They have prolonged immobihty due to their illness and may have further stasis from neopla~tic c?mpression of veins. Furthermore, tumour mvasion, chemotherapy and vascular access catheters affect vessel wall integrity and procoagulant molecules released by tumours pro~ote activatio~of the coagulation cascade. The nsk of developing VTE is two to three times that of benign surgery and may remain high despite thromboprophyla~is. Various therapies have been s~own to be~ffica cious including LMWH, UFH fixed a.nd adJ~sted doses, dextran, oral anticoagulants, intermittent pneumatic compression and graduated compression stockings. In an overview of general surgery, the results of patients with cancer were. as f?llows: low-dose heparin reduced the relative nsk of developing DVT by 53% and PE by 58%; the respective figures for dextran were 46% and 57%. Intermittent pneumatic compression reduced the risk of DVT by 39%, there were too few data to analyse the effect on PE. 16 Green et al. 61 found a lower mortality in cancer patients treated with LMWH than in those treated with UFH. The mechanism of action is unclear but may reflect either the anti thrombotic actions of heparin or a direct antitumour cell effect. Experiments and clinical trials are underway to investigate the effects of LMWH and UFH on tumour biology.
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Summary
LMWHs are becoming firmly established in clinical practice for the prevention of posto'pe~~tive thromboembolic disease. They offer significant advanta~es over UFH in that they hav~a longer half-hie and greater bioavailability at fixed doses and a more predictable anticoagulant response which means they may be administered on a once-daily basis. In general and orthopaedic surgery, where there is the most experience of their use they have been shown to be as effective and as safe as UFH. Recent trials have also demonstrated their efficacy in the treatment of DVT when administered in a fixed subcutaneous dose. This has obvious clinical and economic advantages. The role of LMWHs in renal dia~ysis, cardiopulmonary bypass, medicine and cardiology and arterial surgery requires further investigation.
